Navigation Links
IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial

IDM Pharma, Inc. today presented preliminary results from a Phase II UVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that UVIDEM was well tolerated with evidence of efficacy and induction of immune response in patients with progressive metastatic melanoma.

The data were presented by Merrick I. Ross, M.D., Professor of Surgery, Chief, Melanoma Section, Department of Surgical Oncology at The University of Texas M. D. Anderson Cancer Center in Houston as an oral presentation titled "Clinical and immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi- institutional phase II clinical trial" (# 3004) at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago.

"We are in great need of new drugs to treat our patients with metastatic melanoma" said Dr. Ross. "The preliminary analysis of the phase II clinical trial with IDM Pharma's cancer vaccine, UVIDEM, suggests that several patients with advanced melanoma attained durable control of their disease after a treatment stimulating their own immune system cells. Additionally, the side effects experienced by our patients were minimal," he added.


'"/>




Page: 1

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharma cos must forge Strategic alliances
4. Medicis Pharmaceutical company enters pediatric market
5. Pharma majors gear to supply anti-anthrax drug
6. Pharmacies in for a dose of bitter medicine
7. Andhra Pradesh to set up Pharma City
8. Sun Pharma to launch chiral version of omeprazole soon
9. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
10. Pharmacia may take 51.5 percent Abbott stake
11. Pharmaceutical companies are targeting patients
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...alian Government has announced that it will be spe...ird flu drug Relenza from Biota Holdings. //Austra...er yesterday. The drug had been licensed by Biota...e, but Biota had alleged that GSK failed to market...
...ddenly collapsed on a family in Karawal Nagar area...e children and two adults and injuring four others...ng beside the wall of a school building, which had...eting deputy commissioner of police R.L Meena said...
... Suk the cloning pioneer of South Korea is defendi... upon the editors of Science magazine in Washingto... US scientific magazine, Donald Kennedy said that ...ertainly not ... months' to explain and support hi...
...puncture, Ayurveda, Chinese movement therapies suc...ng are just some of the commonly used alternative ... over Europe. //Perhaps, this is because it’s stro...e conventional medical treatment for cancer with t...
Other Medicine News:Health News:Scientist Calls Upon Media To Retract His Work 2
(Date:9/3/2008)...ollow up results from chronically infected Hepatit... data obtained earlier in 2008, - Study is the f...term antiviral effect of therapeutic Hepati...gly support move into a second generation, vaccin...ing through TLR acti...
(Date:9/3/2008)...Company to Discuss Phase 3 Plans with FDA, PRINCE...ics, Inc.,announced today that it successfully co... of the company,s new, innovative low-dose, once-w...rs to by its internal product,code AG-200-15. The ...t its,primary endpoint of ovulation suppression, c...
(Date:9/2/2008)...t. 3 /- Forest Laboratories...A. today announced results from,two global Phase I...ing,inhaled anticholinergic for the treatment of p... (COPD). In both the ACCLAIM/COPD I&II,(AClidinium...oderate to,Severe COPD Patients) studies, once-dai...
(Date:9/2/2008)...Meets Primary Bone Mineral Density and Secondary E...Company to Host Conference Call and Webcast Wednes...am ET / 5:30 am PT, SAN DIEGO, Sept. 2 /PRNewswir...aq: NBIX ) today announced positive safety and ef...ial using its proprietary, orally-active,nonpeptid...
Breaking Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6A tricky tumor virus 9695 1A tricky tumor virus 9695 2Just hours apart 2 brothers undergo robotic prostate cancer surgery 9693 1Just hours apart 2 brothers undergo robotic prostate cancer surgery 9693 2Relatives who decline organ donations face conflict and guilt 9691 1Relatives who decline organ donations face conflict and guilt 9691 2Relatives who decline organ donations face conflict and guilt 9691 3New gene test for prostate cancer at hand 9689 1New gene test for prostate cancer at hand 9689 2
.../PRNewswire-FirstCall/ --,Nuvelo, Inc. today annou... (R-Spondin1), a secreted protein currently in pre...ecific and potent,stimulator of gastrointestinal (...maged in patients with inflammatory bowel,conditio...is. The,study, entitled "R-Spondin1, A Novel Intes...
...abetes Insulin-Free, WASHINGTON, April 10, 2007 /P... adult stem cell therapy, the Journal of the,Ameri...udy in which,14 of 15 Juvenile Diabetes patients d... an adult stem cell treatment. According,to U.S. R...cant in,that it,s the first attempt at using stem ...
Other Medicine Technology:Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 2Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 3Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 4Newest Adult Stem Therapy Treats Diabetes 2
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: